ArticleInternational journal of endocrinology2018
CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers.
Article in International journal of endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management.Frontiers in endocrinology · 2021Pooled it
- Pooled it
- An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function.Cancer immunology research · 2026Article
- Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies.Journal for immunotherapy of cancer · 2024Article
- CD80-Fc fusion protein as a potential cancer immunotherapy strategy.Antibody therapeutics · 2024Review
- Immunological characteristics of immunogenic cell death genes and malignant progression driving roles of TLR4 in anaplastic thyroid carcinoma.BMC cancer · 2023Article
- Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?Frontiers in oncology · 2023Review
- Is Melanoma Progression Affected by Thyroid Diseases?International journal of molecular sciences · 2022Review
- Review
- Immunotherapy for anaplastic thyroid carcinoma: the present and future.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2021Review
- Papillary Thyroid Cancer Prognosis: An Evolving Field.Cancers · 2021Review
- The Clinical Value of VDR and CTLA 4 in Evaluating the Prognosis of Invasive Duct Carcinoma of Egyptian Patients and their Benefit as a Target Therapy.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Immune Cell Infiltration-Based Characterization of Triple-Negative Breast Cancer Predicts Prognosis and Chemotherapy Response Markers.Frontiers in genetics · 2021Article
- From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer.Theranostics · 2021Review
- Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer.European thyroid journal · 2020Article
- Markers of immune activation: novel biomarkers to predict the early-warning indicator of patients with papillary thyroid carcinoma.Diagnostic pathology · 2020Article
- Immunotherapy in anaplastic thyroid cancer.American journal of translational research · 2020Article
- PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dysregulation of PD-1 ligands (PD-L1 and PD-L2) and CTLA-4 ligands (CD80 and CD86) represents a tumor strategy to escape the immune surveillance. Here, the expression of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.